RTP Mobile Logo

Interview with Jeremy Abramson, MD

Track 1: Biologic rationale for antitumor activity of immune checkpoint inhibitors in Hodgkin lymphoma (HL)
Track 2: Activity of chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma (DLBCL)
Track 3: Immune checkpoint inhibitor-associated pneumonitis
Track 4: Recent FDA approval of ibrutinib for chronic graft-versus-host disease
Track 5: Management of cytokine release syndrome and neurotoxicity in patients undergoing CAR-T therapy
Track 6: Activity of axicabtagene ciloleucel in relapsed/refractory DLBCL
Track 7: Integration of anti-PD-1 checkpoint inhibitors into the therapeutic algorithm for HL
Track 8: Sustained responses to brentuximab vedotin versus checkpoint inhibitors in HL
Track 9: Case: A 46-year-old woman with brentuximab vedotin-refractory HL receives an immune checkpoint inhibitor on a clinical trial
Track 10: AETHERA: Results of a Phase III trial of brentuximab vedotin as consolidation therapy → autologous stem cell transplant (ASCT) for patients with HL at risk of relapse or disease progression
Track 11: Durable responses to brentuximab vedotin for advanced HL
Track 12: Activity and tolerability of immune checkpoint inhibitors for advanced HL
Track 13: Case: A 76-year-old woman with indolent chronic lymphocytic leukemia (CLL) initially observed for more than 5 years is found on repeat FISH testing to have an acquired 17p deletion
Track 14: Selection of first-line therapy for CLL
Track 15: Monitoring and management of tumor lysis syndrome (TLS) in patients starting venetoclax treatment
Track 16: Combining venetoclax with other agents for CLL
Track 17: Acalabrutinib for relapsed/refractory CLL
Track 18: Activity and tolerability of idelalisib for CLL and follicular lymphoma (FL)
Track 19: Case: A 67-year-old woman with Stage IIIA FL that was initially observed now requires treatment
Track 20: Lenalidomide/rituximab (R2) for relapsed/refractory FL
Track 21: Primary results of the Phase III GALLIUM study: Obinutuzumab-based induction and maintenance therapy prolongs PFS for patients with previously untreated FL

Interview with Ajay K Gopal, MD

Track 1: Case: A 52-year-old man with low-grade, symptomatic FL achieves a complete response with bendamustine/rituximab
Track 2: GALLIUM: Results of a Phase III study evaluating rituximab or obinutuzumab with chemotherapy as front-line treatment for FL
Track 3: Treatment algorithm for relapsed FL
Track 4: Idelalisib for relapsed FL
Track 5: Immune-related side effects with idelalisib
Track 6: Incorporating idelalisib with or without rituximab into the treatment of relapsed FL
Track 7: Use of radioimmunotherapy for FL
Track 8: Case: A patient with del(17p) CLL is observed for 2 years before starting ibrutinib
Track 9: Use of ibrutinib for patients receiving anticoagulants
Track 10: Ibrutinib-related atrial fibrillation
Track 11: Molecular testing for patients with progressive CLL
Track 12: Prophylaxis for and management of TLS in patients receiving venetoclax
Track 13: Front-line therapy for younger patients with standard-risk CLL
Track 14: Obinutuzumab for CLL
Track 15: Sequencing idelalisib for CLL
Track 16: Tolerability of PI3K inhibitors, including copanlisib
Track 17: Case: A 66-year-old man with advanced-stage activated B-cell–like (ABC) DLBCL experiences disease progression after R-CHOP and platinum salvage chemotherapy
Track 18: CAR-T therapy-related cytokine release syndrome and neurotoxicity
Track 19: Potential role for ibrutinib and lenalidomide in ABC DLBCL
Track 20: Case: A 60-year-old man with relapsed mantle cell lymphoma (MCL) 2 years after consolidation ASCT receives ibrutinib
Track 21: Up-front and maintenance therapy for younger patients with MCL
Track 22: Initial treatment and maintenance therapy for older patients with MCL
Track 23: Sequencing lenalidomide, bortezomib and venetoclax for relapsed MCL
Track 24: Androgen receptor expression in MCL
Track 25: Ongoing trial of enzalutamide for MCL
Track 26: Case: A 27-year-old woman with bulky Stage II HL and relapse after reinduction therapy and tandem transplant receives brentuximab vedotin and achieves a durable remission
Track 27: Duration of complete responses to brentuximab vedotin in patients with HL
Track 28: Brentuximab vedotin-associated neuropathy
Track 29: Results of the Phase III AETHERA trial of brentuximab vedotin as consolidation therapy after ASCT for patients with HL at risk of relapse or progression
Track 30: Optimal use of checkpoint inhibitors for HL
Track 31: Tolerability and side effects of checkpoint inhibitors
Track 32: Treatment of HL in older patients
Track 33: Initial treatment approach for peripheral T-cell lymphoma not otherwise specified
Jeremy Abramson, MD
Director of the Lymphoma Program
Jon and Jo Ann Hagler
Chair in Lymphoma
Massachusetts General Hospital
Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Ajay K Gopal, MD
Professor, Medical Oncology Division
University of Washington
School of Medicine
Associate Member
Clinical Research Division
Fred Hutchinson
Cancer Research Center
Director of Clinical Research
Hematology Malignancies/Hematology
Seattle Cancer Care Alliance
Seattle, Washington


Neil Love, MD
Research To Practice
Miami, Florida